An Israeli developer and manufacturer of high-quality Active Pharmaceutical Ingredients (API) and selected Finished Dosage Form (FDF) products seeking joint venture or manufacturing agreement

The Israeli company has 30+ years of focus on complex chemistry and uncompromising quality. It offers a variety of tailor-made solutions including: process and analytical development, novel routes of synthesis, material solid state and physical properties design, regulatory expertise, FDF forward integration solutions, Paragraph IV challenge partnerships, contract development and manufacturing services. Looking for partners to help develop and market product globally.
Founded in Israel in 1987, the company develops, manufactures and markets Active Pharmaceutical Ingredients (API) and Finished Dosage Forms (FDF) for generic and branded pharmaceutical companies in more than 50 countries. The company offers over 30 years of focus on complex chemistry and uncompromising culture of quality with exemplary regulatory compliance track record. Main production plant being in Israel with subsidiaries in India and the U.S. The company holds 25 proprietary patents and has filed for additional patents. They have full current Good Manufacturing Practices (cGMP) production, from grams to multi-ton, and is fully compliant with the regulatory requirements of leading health authorities including the U.S. Food and Drug Administration (FDA), the United Kingdom’s Medicines Control Agency, Australia’s Therapeutic Goods Administration, and Canada’s Health Protection Branch. The company is looking for manufacturing agreement and joint venture agreements, to help penetrate new markets around the world, to develop and grow the company.
Type (e.g. company, R&D institution…), field of industry and Role of Partner Sought: 
The company is looking is looking for manufactures to partner over the development and the marketing of Active Pharmaceutical Ingredients and Finish Dosage Forms (drugs) for the different regulatory markets including the US, EU and Japan. Through this manufacturing agreement or joint venture agreement, the company can begin to grow and expand its sales in the process.
Stage of Development: 
Already on the market
Comments Regarding Stage of Development: 
36 commercial APIs, 5 commercial FDFs currently sold to More than 300 generic and branded pharmaceutical customers in over 50 countries. The company also have a wide range of pipeline products that are currently under development.
IPR Status: 
Patent(s) applied for but not yet granted,Patents granted
External code: